The endothelium plays a pivotal role in the progression of solid tumors and is considered a highly relevant target for therapy. However, it emerges that current clinical angiogenesis inhibitors that act through inhibition of tumor-derived growth factors are prone to inducing drug resistance. Therefore, markers of tumor endothelial cells (ECs) themselves provide attractive novel therapeutic targets. In a screen for markers of tumor angiogenesis, we recently identified high-mobility group box 1 (HMGB1), known to act as proinflammatory cytokine and chromatin-binding molecule. Here we report on the role of HMGB1 in angiogenesis by showing that its overexpression is associated with an increased angiogenic potential of ECs. HMGB1 stimulates the expression of players in vascular endothelial growth factor and platelet-derived growth factor signaling, both in vitro and in vivo. Importantly, we show that HMGB1 triggers and helps to sustain this proangiogenic gene expression program in ECs, additionally characterized by increased activity of matrix metalloproteinases, integrins and nuclear factor-kB. Moreover, we found that HMGB1 is involved in several autocrine and/or paracrine feedback mechanisms resulting in positive enforcement of HMGB1 expression, and that of its receptors, RAGE (receptor for advanced glycation end products) and Toll-like receptor 4 (TLR4). Interference in HMGB1 expression and/or function using knockdown approaches and antibody-mediated targeting to break this vicious circle resulted in inhibited migration and sprouting of ECs. Using different in vivo models, therapeutic efficacy of HMGB1 targeting was confirmed. First, we demonstrated induction of HMGB1 expression in the chicken embryo chorioallantoic membrane (CAM) neovasculature following both photodynamic therapy and tumor challenge. We subsequently showed that anti-HMGB1 antibodies inhibited vessel density in both models, accompanied by a reduced vascular expression of angiogenic growth factor receptors. Collectively, these data identify HMGB1 as an important modulator of tumor angiogenesis and suggest the feasibility of targeting HMGB1 for multi-level cancer treatment.
INTRODUCTION
Angiogenesis is essential for most solid tumors to progress, and the inhibition of blood vessel growth is considered to be of therapeutic benefit.
1,2 Molecular targeting of tumor-derived growth factors (for example, vascular endothelial growth factor (VEGF)) or receptors (for example, epidermal growth factor receptor (EGFR)) has shown promise; however, improvement with these compounds is moderate and---like with conventional chemotherapeutics---drug resistance proved to be an issue. 3 Therapeutics aimed specifically at destroying or inhibiting the tumor vasculature are believed to be less susceptible to acquired drug resistance. 2, 4 Hence, for more direct intervention in the underlying mechanisms of tumor progression, the molecular characterization of tumor endothelium promises the elucidation of novel relevant drug targets. 4, 5 We used gene expression profiling of endothelial cells (ECs) isolated from freshly resected colon tumors, normal colon tissue and placenta to identify genes that showed specific induction during tumor angiogenesis. 6, 7 Here, we identified high-mobility group box 1 (HMGB1) as a tumor angiogenesis gene. 6 HMGB1 was initially discovered as a nuclear chromatin-binding protein, 8 although an extracellular role for HMGB1 was later demonstrated on filopodia of migrating neuronal cells. 9 Subsequently, a cytokine function for HMGB1 emerged, first in inflammation processes 10, 11 and then, more recently, HMGB1 has been recognized as a cytokine mediator of angiogenesis. 6, 12, 13 Typically, tumors contain multiple sources of HMGB1 that can act in concert to enhance progression and contribute to the development of therapy-refractory metastatic disease. 14 --16 In the present study, we investigated the contribution of HMGB1 to tumor angiogenesis, and demonstrate its clinical relevance as a therapeutic target. Using molecular and cellular studies, we show that HMGB1 stimulates the migratory and sprouting capacity of ECs in vitro and in vivo. We demonstrate that this response is accompanied by the induction of a proangiogenic gene expression program that is sustained in an autocrine or paracrine fashion. Interference with HMGB1 or its receptor RAGE (receptor for advanced glycation end products) attenuated these effects. We further show that HMGB1 expression is induced during tumor angiogenesis, both in human tumors and in experimental models. Importantly, we provide original evidence that antibody targeting of HMGB1 inhibits tumor angiogenesis in vivo in the chicken embryo chorioallantoic membrane (CAM) as monotherapy, as well as in combination with photodynamic therapy (PDT), demonstrating its direct relevance to the treatment of cancer patients.
RESULTS

HMGB1 expression is induced in TECs
HMGB1 overexpression has been associated with the progression of different types of tumors, 14,17 --19 a process governed by active angiogenesis. We recently identified HMGB1 as a specific marker of tumor endothelium, 6 and decided to further investigate the contribution of this protein to tumor angiogenesis. We confirmed overexpression of HMGB1 in freshly resected colorectal carcinoma samples by quantitative PCR (qPCR) (Figure 1a ) as well as in public gene expression repositories (Figure 1b) . In tissue sections of colorectal and ovarian tumors, HMGB1 protein was detected in different cells types, including endothelium. HMGB1 staining was observed in both the nuclei and cytoplasm of cells (Figure 1c and Supplementary Figure S1 ). ECs isolated from clinical samples (human colorectal tumor tissue and patient-matched normal colon tissue 6 ) were used to profile HMGB1 expression. Specific induction of HMGB1 in colon tumor ECs (TECs) over normal colon tissue ECs (NECs) was confirmed by qPCR analysis of sorted cells and by flow cytometry using CD31-and HMGB1-specific antibodies (Figure 1d ). These observations confirm and extend the notion that HMGB1 is a tumor angiogenesis marker.
Next, we determined whether endothelial HMGB1 expression is affected by angiogenic stimulation. As ECs become activated in culture, expression was assessed in human umbilical vein endothelial cells (HUVECs) that were either used immediately after isolation (native) or cultured for 3 days in serum containing medium (normal). Expression of HMGB1 is markedly induced Figure 1 . HMGB1 is overexpressed in tumor endothelium and parallels EC activation. (a) Fresh frozen tissue of colorectal tumors and patientmatched normal colon (N ¼ 7) were lysed and total RNA was isolated. HMGB1 mRNA levels were determined by qPCR. *Po0.025, paired t-test. (b) HMGB1 mRNA expression levels in colorectal tumor and normal colon tissues in expression profiling studies retrieved from Oncomine (Compendia Biosciences, Ann Arbor, MI, USA). Median values of the study population are shown. (c) Immunohistochemical staining of HMGB1 and CD31/CD34 in paraffin sections of colorectal tumor (T) and normal colon tissue (N). Scale bar, 100 mm. Arrows indicate blood vessels with HMGB1 expression. (d) HMGB1 mRNA and protein in ECs isolated from colon tumor ECs (TECs) and normal colon ECs (NECs) (N ¼ 6) were quantified by qPCR (left) and flow cytometry (right), respectively. Data were normalized to expression levels in NECs. *Po0.025 (paired t-test). (e) HMGB1 transcript expression in cultured ECs. HUVECs were either processed for mRNA extraction directly after isolation from the umbilical cords (native), after 3 days in culture following isolation (Normal) or in routinely cultured early-passage (P1 --P3) HUVECs that were silenced by serum starvation (0.2% fetal calf serum (FCS)) for 2 days. *Po0.05 (Mann --Whitney U-test). Figure 2 . HMGB1 induces an angiogenic phenotype. (a) RF24 cells were grown to confluence and a uniform scratch wound was made in the monolayer. Cells were treated with either bFGF (20 ng/ml) or rHMGB1 (500 ng/ml; from WA Buurman) and wound size was measured at T ¼ 0 and T ¼ 6 h by computational analysis. Migration was expressed as wound closure relative to control cells. (b) Bovine capillary ECs (BCEs) were grown on gelatin-coated beads and embedded in collagen in the presence or absence of bFGF (20 ng/ml) or rHMGB1 (500 ng/ml; from WA Buurman). After 24 h, sprout length was assessed using ImageJ. Sprouting of untreated cells (control) is set to 100%. (c) RF24 cells were treated as described above and profiled for angiogenic gene expression by qPCR. Expression of untreated cells was set to 1. *Po0.05 t-test. ND, not determined. (d, e) RF24 cells were treated as described above. NF-kB subunit p65 activity was determined by target sequence binding enzyme-linked immunosorbent assay (ELISA; d), and NF-kB target genes ICAM1, VCAM1 and E-selectin (SELE) were determined by qPCR (e). Expression of untreated cells is set to 1. *Po0.05, **Po0.025 (t-test); # Po0.05 (Mann --Whitney U-test). Note: mRNA levels were below detection limit. during initiation of cell culture (Figure 1e) . In established cultures, silencing of ECs by serum deprivation markedly suppressed HMGB1 expression (Figure 1e ). Together, these data indicate that HMGB1 expression parallels EC activation.
HMGB1 promotes EC migration and sprouting
In recent years, different roles and cellular localizations of HMGB1 have been described. Next to its chromatin-binding properties, HMGB1 is recognized as a proinflammatory cytokine, thereby fulfilling both nuclear and extracellular roles. 20 To this end, HMGB1 can be passively released as well as actively secreted from cells. 11, 21 ECs have been shown to secrete HMGB1 after activation, 22 and moreover, are activated themselves by exposure to HMGB1. 12, 13, 23, 24 To further understand the contribution of this extracellular HMGB1 fraction to tumor angiogenesis, we treated ECs with recombinant HMGB1 (rHMGB1) to mimic the activity of HMGB1. Based on previous reports, 12, 13 and as the protein activity may be compromised by oxidation over time, 25 RF24 cells were exposed to 50 and 500 ng/ml HMGB1 from different sources and assayed for migration. Although 50 ng/ml was not always effective (Supplementary Figure S2) , 500 ng/ml rHMGB1 increased EC migration in a scratch wound assay ( Figure 2a ) and sprouting of bovine capillary ECs into a collagen gel (Figure 2b) . No effect on cell proliferation was observed (data not shown). The effect on primary (HUVECs) and immortalized ECs (RF24) was comparable (Supplementary Figure S2a) , and addition of polymyxin B to neutralize possible lipopolysaccharide contamination did not affect these results (data not shown).
HMGB1 induces a proangiogenic gene expression program in vitro and in vivo
We further investigated the effects of HMGB1 on ECs to understand the mechanisms behind its proangiogenic actions. We employed qPCR to profile the expression of a panel of angiogenesis-related genes. RF24 cells were treated with basic fibroblast growth factor (bFGF; 20 ng/ml) or rHMGB1 (500 ng/ml) for 24 h. rHMGB1 treatment of ECs induced a proangiogenic gene expression program evidenced by the induction of vascular endothelial growth factor A (VEGFA) and its receptors, VEGF receptors 1 and 2 (VEGFR1 and VEGFR2) and neuropilin-1 (NRP1). It is noteworthy that HMGB1 and VEGFA expression correlate in cancer (Supplementary Figure S3) . In addition, platelet-derived growth factor receptors were induced, as were integrins and matrix metalloproteinases (MMPs). No significant effects on Angiopoietins (Ang), Tie1, Tie2 and fibroblast growth factor receptor were observed (Figure 2c ). The proinflammatory leukocyte adhesion molecules, ICAM1 (intercellular adhesion molecule 1), VCAM1 (vascular cell adhesion molecule 1) and E-selectin (SELE), which are downregulated under the influence of bFGF, 26 were upregulated in response to HMGB1 (Figure 2e ), in concordance with previous reports. 22 --24 In addition, we confirmed the Images were analyzed and quantified for different vascular parameters (b). (c) Gene expression in the CAMs treated with 500 ng/ml rHMGB1 was determined using qPCR. Expression relative to reference genes (ACTB and PPIA), related to the difference in threshold cycle (Ct) value, is shown to indicate relative mRNA levels of the different genes.
induction of nuclear factor (NF)-kB activation upon HMGB1 stimulation ( Figure 2d ). Furthermore, the activity of MMP2 was markedly increased after treatment with rHMGB1, as was the expression of activated ITGB1 (Supplementary Figure S4) . Taken together, treatment of ECs with rHMBG1 contributes to a higher expression and activation of proteins involved in proangiogenic signaling, remodeling of and interactions with extracellular matrix (MMPs and integrins), all important processes during tumor angiogenesis. 5 To determine the effect of rHMGB1 on angiogenesis in vivo, chicken CAMs were treated with human rHMGB1, which shares 99% sequence similarity with chicken HMGB1 protein. Development of vessels in the CAM is a highly organized process, and results in a dense vascular system with a very regular morphology. Treatment of the CAMs with rHMGB1 in different concentrations disorganized this process, and revealed irregular sprouting and intussusceptive vessel growth at the microvascular level ( Figure 3a) . Furthermore, arterioles and venules appear dilated, and directional persistence of these vessels is decreased. Branching of capillaries increased, whereas the mean vascular mesh size decreased, although this was only significant for the highest concentration of rHMGB1 (Figure 3b) . At the macrovascular level, treatment of the CAMs with rHMGB1 resulted in an increased vessel density, but also clearly induced dilatation of the vessels (Supplementary Figure S5) . Moreover, the gene expression pattern induced by HMGB1 in vitro was recapitulated in vivo ( Figure 3c ). In particular, VEGF receptor and platelet-derived growth factor receptor expression were increased, which can explain the observed increase in vessel density as well as dilatation.
HMGB1 sustains a proangiogenic regulatory loop HMGB1 can act through different receptors, including RAGE 27 and Toll-like receptors (TLRs) 2 and 4.
28 RAGE is a multiligand receptor of the immunoglobulin superfamily, whereas TLRs are receptors of the innate immune system. 16, 27, 28 RAGE and TLR4 were detected in different types of cultured ECa (Supplementary Figure S6a) , although TLR2 expression was very low (data not shown).
Given the reports that RAGE and TLR expression can be induced by NF-kB activation, 16, 28, 29 we set out to determine whether exposure of ECs to HMGB1 induces a positive autocrine feedback circuit through induction of its own receptors. Indeed, stimulation of ECs with rHMGB1 resulted in increased TLR4 and RAGE expression (Figure 4a ). In addition, it also induces expression of endogenous HMGB1 (Figure 4a ). Hence, stimulation with rHMGB1 acts to sustain a proangiogenic response at multiple levels. rHMGB1 induces expression of angiogenic growth factors and their receptors, as well as expression of endogenous HMGB1 and its receptors.
These observations led us to investigate whether increased HMGB1 expression was also accompanied by an increased secretion to further sustain this self-enforcing regulation. HMGB1 continuously shuttles between the nucleus and the cytoplasm, and protein modifications such as phosphorylation and acetylation prevent it from re-entering the nucleus. 30 As such, cytoplasmic accumulation of modified HMGB1 precedes secretion. 10, 30, 31 Hence, nuclear and cytoplasmic lysates were probed on western blot with anti-HMGB1 antibodies to quantify the relative amounts of cytoplasmic HMGB1. In nuclear extracts, two protein bands were detected by the antibody, but only the larger protein was detected in the cytoplasmic fraction, suggesting this larger protein is the post-translationally modified HMGB1 that is to be secreted (Figure 4b and Supplementary Figure S4 ). Both bFGF and rHMGB1 increased the relative fraction of HMGB1 in the cytoplasm (Figure 4b ), as well as in the culture medium as measured by enzyme-linked immunosorbent assay (Figure 4c ), providing further evidence for a positive autocrine or paracrine feedback mechanism of HMGB1 in promoting angiogenesis.
Antagonizing HMGB1 reverses the angiogenic phenotype As we have shown that HMGB1 stimulates angiogenesis and induces angiogenic gene expression (Figures 2 --4) , we next investigated whether inhibition of HMGB1 expression counteracts this phenotype. HMGB1-specific small interfering RNA (siRNA) treatment of ECs resulted in a marked (80%) reduction of HMGB1 expression (Figure 5a ). HMGB1 knockdown only minimally (a) RF24 cells were treated for 3 days with bFGF (20 ng/ml) or rHMGB1 (500 ng/ml, Sigma-Aldrich), and expression of HMGB1 and its putative receptors RAGE and TLR4 was determined by qPCR. (b) RF24 cells treated with rHMGB1 or bFGF as above were lysed and nuclear and cytoplasmic fractions were isolated and transferred to nitrocellulose for detection of HMGB1 by western blotting. Band intensities were quantified and normalized to actin expression, and expressed relative to untreated control cells. (c) HMGB1 secreted into the culture medium was measured using enzyme-linked immunosorbent assay (ELISA). Cells were treated with the indicated concentrations of rHMGB1 for 16 h, and secreted HMGB1 was measured 8 h later in fresh medium. All panels: *Po0.05, **Po0.025, Mann --Whitney U-test.
HMGB1 contributes to tumor angiogenesis JR van Beijnum et al affected EC proliferation, although it resulted in a reduced capacity of the ECs to migrate and sprout under the influence of bFGF (Figure 5a ). In concordance with these data, we demonstrated that overexpression of HMGB1 induced migration but not proliferation (Supplementary Figure S7) . Moreover, HMGB1 knockdown led to a concomitant suppression of genes of the VEGF/VEGFR axis, MMPs and adhesion molecules (Figure 5b ), opposing the actions of rHMGB1 treatment (Figure 2) .
Having demonstrated that HMGB1 expression and secretion are induced by bFGF, (Figure 4) , we determined the effects of antagonizing HMGB1 with antibodies. To this end, HUVECs were stimulated with bFGF and proliferation, apoptosis and migration were measured in the presence or absence of anti-HMGB1 antibodies. No effects of anti-HMGB1 antibodies on EC proliferation or apoptosis were detected (Supplementary Figure S8a and b) . In contrast, anti-HMGB1 antibodies inhibited EC migration in a dosedependent manner (Figure 5c ). In addition, sprouting of ECs from beads was found to be inhibited by the antibody treatment (Figure 5d ), as was sprouting of capillaries from an explanted human tumor blood vessel fragment (Figure 5e ). Taken together, these data show that interference with functional HMGB1 expression impairs angiogenesis in vitro, accompanied by reversal of angiogenesis-related gene expression.
Functional inhibition of RAGE abrogates HMGB1-induced proangiogenic responses HMGB1 expression is increased in angiogenic ECs, and is involved in a proangiogenic feedback mechanism through induction of its own expression and secretion as shown above. We therefore questioned whether interfering with its receptors was capable of breaking this proposed self-sustaining circle. To this end, RAGE and TLR4 expression were functionally suppressed using siRNA and antibodies. Knockdown of HMGB1, RAGE and TLR4 expression was achieved through siRNA treatment (Figure 6b) . Interestingly, where rHMGB1 increases RAGE and TLR4 expression (Figure 4a) , knockdown of HMGB1 mRNA did not significantly affect RAGE and TLR4 levels (Figure 6b, black bars) . In contrast, knockdown of RAGE and TLR4 significantly reduced HMGB1 mRNA levels, although this was not accompanied by a reduction in VEGFA and VEGFR1 mRNA levels (Figure 6b ). The bFGF-induced migration of ECs was inhibited by siRNA-mediated knockdown of, and antibodies directed against, HMGB1 and RAGE, but not TLR4 (Figures 6a  and e) . Together, these data suggest a more dominant role for RAGE in mediating the angiogenic effects of HMGB1. Indeed, as shown in Supplementary Figure S6 , RAGE expression is induced in TECs whereas the expression of TLR4 is suppressed, indicating that RAGE is the main HMGB1 receptor in tumor endothelium in vivo.
Importantly, migration induced by rHMGB1 was attenuated in RAGE-but not TLR4-targeting siRNA-treated cells (Figure 6c ). Not only migration of ECs was affected, but induction of ICAM1 expression was also compromised by knockdown of HMGB1 and RAGE (Figure 6d ). In addition, antibodies against both HMGB1 and RAGE also blocked rHMGB1-induced migration (Figure 6e) , as well as the induction of endogenous HMGB1 expression (Figure 6f) , and, partially, VEGFA, VEGFR1 and VEGFR2 (Figure 6g) . Thus, siRNA and antibodies targeting HMGB1 and RAGE, but not TLR4, resulted in reduced responsiveness to exogenous HMGB1, stressing the relevance of the HMGB1-RAGE ligand-receptor pair in angiogenesis. Interplay between HMGB1 and its receptors. (a) RF24 cells were subject to treatment with siRNA against HMGB1 or its receptors and migration was measured using a scratch wound assay. Wound closure after 6 h is expressed as a percentage of control siRNA (siCtrl)-treated cells. (b) RF24 cells were treated as described above, harvested and processed for RNA isolation. Expression of HMGB1 and its receptors, as well as VEGFA and VEGFR1, was measured by qPCR and expressed relative to siCtrl-treated cells. Values o100% are presented below the x axis to indicate suppression. (c) siRNA-treated RF24 cells as described above were analyzed for migration in the presence and absence of rHMGB1 (500 ng/ml; HMGBiotech). All values were per siRNA treatment normalized to control treated cells. (d) ICAM1 protein expression induced by rHMGB1 (500 ng/ml; Sigma-Aldrich) was measured by flow cytometry in siRNA-treated RF24 cells. ICAM1 expression levels are presented relative to that of untreated cells. (e) RF24 cells were subject to analysis of migration in the presence or absence of anti-HMGB1 or anti-RAGE antibodies (10 mg/ml; left panel). Alternatively, RF24 cells were pretreated for 1 h with anti-HMGB1 or anti-RAGE antibodies (10 mg/ml) and subsequently subject to migration analysis in the presence and absence of rHMGB1 (500 ng/ml; HMGBiotech) as described above (right panel). (f ) rHMGB1-induced HMGB1 expression was evaluated in ECs treated with antibodies against HMGB1 and RAGE as described under (e). Expression levels are shown relative to that of untreated cells. (g) Expression of VEGFA, VEGFR1 and VEGFR2 was determined by qPCR in RF24 cells treated with or without anti-HMGB1 or anti-RAGE antibodies as described above. Expression is presented relative to untreated cells. *Po0.05, **Po0.025 t-test (b) or Mann --Whitney U-test (a, c --f ).
Targeting HMGB1 inhibits tumor angiogenesis in vivo
To determine the relevance of HMGB1 as an angiogenesis target in vivo, we employed the chicken embryo CAM model. The CAM is a powerful tool to study tumor growth and developmental and treatment-regulated angiogenesis. 32 --34 We verified and proved that our antibody was capable of detecting chicken HMGB1 (Supplementary Figure S8d) . Topical application of antibody decreased vascular density (Supplementary Figure S8e) . In an alternative in vivo model of angiogenesis, PDT was applied to induce vascular occlusion and subsequent neoangiogenesis. We have previously shown that following PDT, capillary sprouting is induced, resulting in revascularization of the treated area over a period of 48 h. 34 We now found that this angiogenic response was accompanied by a marked induction of HMGB1 in the CAM, as determined by qPCR (Figure 7a ). Treatment with anti-HMGB1 antibodies following PDT markedly inhibited the regrowth of vessels within the PDT-treated area and increased the vascular mesh size (Figure 7a) .
To demonstrate the feasibility of antibody targeting of HMGB1 to inhibit tumor angiogenesis in vivo, CAMs were inoculated with human tumor cell spheroids. Whereas spheroids created from the human LS174T colorectal carcinoma cell line reside merely topically on the CAM as small nodules (Supplementary Figure  S8f) , the human ovarian carcinoma cell line A2780 forms fast growing, highly angiogenic tumors underneath the CAM in ovo (Figure 7b ). This is accompanied by an induction of vascular HMGB1 expression. Treatment of the CAM tumors with anti-HMGB1 antibodies reduced microvessel density in the vicinity of the tumor (Figure 7c and Supplementary Figure S8) .
In all, the effects on developmental CAM angiogenesis, PDTinduced angiogenesis and tumor angiogenesis suggest that antibody-mediated targeting of HMGB1 is an effective strategy to inhibit tumor angiogenesis and tumor growth. Taken together, antibody targeting of HMGB1 inhibits angiogenesis, which may be mediated by interference in the positive angiogenic feedback loop that HMGB1 helps to maintain, either between ECs only or between ECs and tumor cells (Figure 8) .
DISCUSSION
In the present study, we investigated the angiogenic functions of HMGB1, and show that its elevated expression in TECs can contribute to positive feedback mechanisms that favor sustained angiogenic signaling. Moreover, we demonstrate that interference in this process reduces tumor angiogenesis, suggesting that targeting HMGB1 expression and/or signaling may provide clinical benefit in the treatment of cancer.
In ECs, HMGB1 induces the secretion of proinflammatory cytokines such as tumor necrosis factor-a and interleukin-8, and the expression of leukocyte adhesion molecules ICAM1, VCAM1 and E-selectin (SELE) through NF-kB activation. 22 --24 In turn, ECs secrete HMGB1 in response to tumor necrosis factor-a treatment, 22 suggesting a role for HMGB1 in a positive feedback loop promoting inflammation. Here, we propose a role for HMGB1 in sustaining a proangiogenic response through an autocrine or paracrine feedback loop that acts on several levels. First, we showed that HMGB1 mRNA, cytoplasmic protein fraction and secretion were increased upon EC activation by angiogenic growth factors and by HMGB1 itself (Figures 1 and 4) . Second, stimulation of angiogenesis by HMGB1 is accompanied by the induction of a proangiogenic gene expression program, including the expression of VEGF and its receptors, in vitro and in vivo (Figures 2 and 3 ). Functional interference with HMGB1 or RAGE showed opposite effects ( Figure 6) . Third, the expression of HMGB1 receptors RAGE and TLR4 was increased by exogenous HMGB1 (Figure 4) , which can further amplify the proangiogenic response. The clinical relevance of these findings is underscored by the observation that not only HMGB1 but also its receptor RAGE are overexpressed in TECs (Figure 1 and Supplementary Figure S6) .
Additional evidence for the involvement of HMGB1 in autocrine or paracrine signaling in tumor endothelium stems from the observation that activation of RAGE can increase its own expression through NF-kB-mediated transcriptional activation. 29 In addition, nuclear HMGB1 can facilitate NF-kB-dependent transcription. 35 Moreover, HMGB1 stimulates its own secretion via protein kinase C activation 31 and C-reactive protein, mediated via p38. 36 Indeed, RAGE and TLR4 signaling can both converge to the activation of extracellular signal-regulated kinases 1 and 2, p38 and NF-kB, 12,16,22 --24 leading to transcription and activation of proangiogenic and proinflammatory target genes (Figure 8) .
In a tumor setting, multiple sources of HMGB1 exist. Necrotic tumor cells may leak HMGB1 into the extracellular space, whereas tumor-associated macrophages can actively secrete HMGB1 and VEGF. Taken together, HMGB1 exerts pleiotropic effects, stimulating tumor growth, metastasis and angiogenesis. Figure 8 schematically models these possible HMGB1-mediated autocrine and paracrine feedback mechanisms.
Using the CAM as a model system to study angiogenesis, we have demonstrated that neoangiogenesis induced by PDT and by tumor challenge is accompanied by increased expression of HMGB1 in the vasculature in vivo (Figure 7) . Anti-HMGB1 antibodies were able to counteract new blood vessel formation in these models, demonstrating that functional blocking of endothelial HMGB1 acts as a brake in the process of angiogenesis. Moreover, it emphasizes the clinical potential of combining PDT with angiogenesis inhibition to treat hollow organ tumors such as esophageal and bladder cancers. From our data, we cannot completely exclude possible influence of tumor-derived HMGB1 that may compete for antibody binding with EC-derived HMGB1, although blocking tumor-born fraction of HMGB1 will undoubtedly contribute to decreased angiogenesis by interfering with EC activation (Figure 8) .
The overexpression of HMGB1 in TECs 6 and its proangiogenic cytokine activity make HMGB1 an attractive candidate molecule for targeting. Recently, the idea of inhibiting tumor angiogenesis by targeting HMGB1 was supported by the postulated hypothesis that HMGB1 A-box, which antagonizes HMGB1 function by competitive binding to RAGE, could be used as an antiangiogenic agent. 37 In analogy to that, several naturally occurring compounds, including ethyl pyruvate, thrombomodulin, cholinergic agonists and green tea polyphenols, 38 can inhibit HMGB1-RAGE signaling, either by direct sequestration of HMGB1 or by inhibiting its secretion. In a study by Taguchi et al., 39 blocking HMGB1-RAGE interactions using different signaling deficient RAGE molecules and antibodies, inhibited tumor growth and invasion in mice. Unfortunately, the vascularization of the tumors after treatment was not addressed in this study, but we can speculate that this was, at least in part, mediated by an inhibition of angiogenesis. A recent study showed VEGF upregulation in response to HMGB1 administration to ischemic hindlimb muscles in mice. Intramuscular transfection of sFlt1 (soluble fms-like tyrosine kinase-1), which neutralizes VEGF, partially attenuated the HMGB1-mediated increase in blood flow. 40 As discussed above, several lines of evidence link RAGE and HMGB1 to tumor progression, metastasis and angiogenesis, putatively involving VEGF. However, targeting HMGB1 rather than VEGF offers the advantage of multilevel inhibition of angiogenesis, as HMGB1 affects expression of not only VEGF but also of other angiogenic signaling mediators, invasion and adhesion molecules as shown above. Moreover, as evasive resistance to anti-VEGF-based therapies appears to become increasingly clinically relevant, targeting HMGB1 seems an attractive alternative.
Although intensely studied, the precise mechanism of action and relative contribution of HMGB1 to angiogenesis, inflammation, cancer and immunity are not clear yet. From our data, it is difficult to establish whether solely extracellular HMGB1 plays a major role in tumor angiogenesis. As HMGB1 has many potential roles in transcription mediation, nuclear roles of the protein should not be neglected. It was recently postulated that overexpression of HMGB1 is associated with all hallmarks of cancer, 15 ranging from invasion, angiogenesis, evasion of apoptosis and insensitivity to growth arrest signals, the latter being affected by intranuclear interactions of HMGB1 with transcription factors or tumorsuppressor genes like NF-kB, 14 pRB and p53. 15 Our data contribute to this view by providing evidence of an angiogenic gene expression program induced and sustained by HMGB1.
In conclusion, we have shown that overexpression of HMGB1 is associated with increased angiogenesis. Furthermore, we demonstrated that HMGB1 induces a gene expression signature that may mediate its proangiogenic activity. We propose a role for HMGB1 in autocrine and paracrine regulation of angiogenic gene expression in ECs that contributes to tumor growth and angiogenesis. Finally, we demonstrated the feasibility of targeting HMGB1 with antibodies to inhibit tumor angiogenesis.
MATERIALS AND METHODS
Isolation of TECs
ECs were isolated from freshly resected colorectal tumors and patientmatched normal colon as described previously. 6, 7 Briefly, tissues were minced, collagenase digested and ECs were isolated using a combination of anti-CD31 and anti-CD34 antibody (DAKO, Glostrup, Denmark)-coated magnetic beads (Life Technologies, Bleiswijk, The Netherlands).
Cell culture and reagents
Primary HUVECs were routinely isolated from umbilical cords. HUVECs and RF24 cells (immortalized HUVECs) 41 were cultured in RPMI supplemented with 10% fetal calf serum, 10% human serum (HUVECs only) and 1% penicillin/streptomycin, and grown in 1% gelatin-coated tissue culture flasks. 42 Where 'native' HUVECs were used, cells were processed immediately after isolation from the cords. Where indicated, bFGF (20 ng/ml, Reliatech, Wolfenbü ttel, Germany) or rHMGB1 (cell culture grade, endotoxin free; Sigma-Aldrich (Zwijndrecht, The Netherlands), HMGBiotech (Milano, Italy) or gift of WA Buurman) were added to serum-free medium. Antibodies (mouse-anti-human HMGB1, Sigma-Aldrich; rabbit-anti-human RAGE, Abcam, Cambridge, UK) were dialyzed to phosphate-buffered saline (for cell culture applications) or NaCl (for CAM) to remove traces of azide.
Transfection of cells with siRNA and pDNA is described in detail in the Supplementary Text. Details on biochemical and cellular phenotype analysis (immunohistochemistry, flow cytometry, western blot analysis and protein activity measurements) are also presented in the Supplementary Text. Migration, sprouting, proliferation and apoptosis assay Cells were plated in gelatin-coated 96-well plates at 5000 (HUVECs) or 15 000 (RF24) cells per well and grown to confluence in 3 days. Wells were uniformly scratched using a guided 96-well pin tool (Peira, Turnhout, Belgium) to create wounds of approximately 300 mm wide. Wells were washed with phosphate-buffered saline, and fresh medium, with or without compounds as indicated, was added. Images were automatically captured on a Leica DMI3000 microscope (Leica, Rijswijk, The Netherlands) using Universal Grab 6.3 software (DCILabs, Keerbergen, Belgium). Scratch sizes were determined using Scratch Assay 6.2 (DCILabs), and absolute wound closure (mm 2 ) was expressed as a percentage of control wells. Proliferation assay using 3 H-thymidine incorporation, apoptosis assay using propidium iodide and sprouting of ECs into collagen gel 42 are described in detail in the Supplementary Text.
Chicken embryo CAM assay
Fertilized chicken White Leghorn eggs were incubated in a hatching incubator with a relative air humidity of 65% and a temperature of 37 1C. CAMs were treated from EDD6-9 with rHMGB1 at the indicated concentrations. Vasculature was visualized by injection of fluoroscein isothiocyanate-conjugated dextran (20 kDa, Sigma) as previously described. 34, 43 Fluorescence images were acquired with an F-view II 12-bit monochrome Peltier-cooled digital CCD camera driven with analySIS DOCU software from Soft Imaging System, Munster, Germany. 44 Vascular density and morphology were analyzed by digital assessment using ImageJ (NIH, Bethesda, MA, USA) based on the macro described previously. 33, 34 Figure 8. Autocrine and paracrine actions by HMGB1 during tumor angiogenesis. HMGB1 can act in both paracrine and autocrine ways to influence tumor angiogenesis. Activation of ECs by, for example, bFGF can induce expression and secretion of HMGB1. Extracellular HMGB1 can in turn activate RAGE and/or TLRs to increase angiogenic activation and/or inflammation. In addition, HMGB1 released from necrotic tumor cells (TCs) or activated tumor-associated (proangiogenic) macrophages (TAMs) can activate ECs to further amplify HMGB1 signaling. Finally, HMGB1 can suppress immunosurveillance by inducing macrophage or dendritic cell (DC) apoptosis.
